We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Personalis Inc (PSNL) USD0.0001

Sell:$2.48 Buy:$2.97 Change: $0.04 (1.39%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Change: $0.04 (1.39%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Change: $0.04 (1.39%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.

Contact details

6600 Dumbarton Circle
United States
+1 (650) 7521300

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$154.78 million
Shares in issue:
51.94 million
Life Sciences Tools & Services
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Christopher Hall
    President, Chief Executive Officer, Director
  • Aaron Tachibana
    Chief Financial Officer, Chief Operating Officer, Senior Vice President
  • Richard Chen
    Executive Vice President - Research and Development, Chief Medical Officer
  • Stephen Moore
    Senior Vice President, Chief Legal Officer, and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.